New DRUG APPROVALS Xenoview™ (xenon Xe hyperpolarized) for Oral Inhalation Date of Approval: December 23, 2022 Company: Polarean Imaging plc Treatment for: Diagnosis and Investigation Xenoview (xenon Xe 129 hyperpolarized) is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. Sunlenca® (lenacapavir) Injection and Tablets Date of Approval: December 22, 2022 Company: Gilead Sciences, Inc. Treatment for: HIV Infection Sunlenca (lenacapavir) is a long-acting HIV-1 capsid inhibitor for use in combination with other antiretroviral(s) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection. Lunsumio™ (mosunetuzumab-axgb) Injection Date of Approval: December 22, 2022 Company: Genentech, Inc. Treatment for: Follicular Lymphoma Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager for the treatment of relapsed or refractory follicular lymphoma. Tzield™ (teplizumab-mzwv) Injection Date of Approval: November 17, 2022 Company: Provention Bio, Inc. Treatment for: Delaying the Onset of Stage 3 Type 1 Diabetes Tzield (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News BIOTHERAPEUTICS 6 A PUBLICATION